ArticleAACE endocrinology and diabetes
Durvalumab-Induced Hypoparathyroidism.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: There have been more reported immune-related adverse events with increasing use of immune checkpoint inhibitors (ICIs) in the treatment of cancers. A range of endocrinopathies have been reported; however, ICI-induced hypoparathyroidism remains a rare immune-related adverse event. The objective of this report is to describe a rare case of durvalumab-induced hypoparathyroidism. Case Report: We describe a case of a 64-year-old man who presented to the emergency department with acute symptomatic hypocalcemia 2 years after completion of durvalumab treatment for stage III non-small cell lung cancer, who had a suppressed parathyroid hormone level, which persisted with correction of calcium levels. Discussion: ICI-induced hypoparathyroidism is a rare entity with only few cases reported in the literature, the mechanism for which remains unclear. Persistence of hypoparathyroidism despite discontinuation of immunotherapy makes inflammation and immune-mediated destruction a possible explanation. Conclusion: This case reinforces the need for an increased awareness and recognition of durvalumab-induced hypoparathyroidism, in addition to more investigation into its underlying mechanisms and potential management options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.